Edition:
India

Exact Sciences Corp (EXAS.OQ)

EXAS.OQ on NASDAQ Stock Exchange Capital Market

45.27USD
25 Apr 2018
Change (% chg)

$-1.66 (-3.54%)
Prev Close
$46.93
Open
$47.09
Day's High
$47.44
Day's Low
$44.87
Volume
943,396
Avg. Vol
793,799
52-wk High
$63.60
52-wk Low
$23.71

Chart for

About

Exact Sciences Corporation is a molecular diagnostics company. The Company focuses on the early detection and prevention of some forms of cancer. It offers a non-invasive screening test called Cologuard for the early detection of colorectal cancer and pre-cancer. Its Cologuard test is a stool-based deoxyribonucleic acid (sDNA)... (more)

Overall

Beta: 0.86
Market Cap(Mil.): $5,889.85
Shares Outstanding(Mil.): 120.94
Dividend: --
Yield (%): --

Financials

BRIEF-Mark Stenhouse To Join Exact Sciences As President, Cologuard

* MARK STENHOUSE TO JOIN EXACT SCIENCES AS PRESIDENT, COLOGUARD

20 Mar 2018

BRIEF-Exact Sciences Q4 Loss Per Share $0.18

* ANTICIPATES COMPLETED COLOGUARD TEST VOLUME OF 900,000-920,000 TESTS DURING 2018.

23 Feb 2018

BRIEF-Exact Sciences announces upsize, pricing of $600 mln of 1 pct convertible senior notes due 2025

* EXACT SCIENCES ANNOUNCES UPSIZE AND PRICING OF $600 MILLION OF 1.0% CONVERTIBLE SENIOR NOTES DUE 2025

12 Jan 2018

BRIEF-Exact Sciences Offers $500 Mln Convertible Senior Notes Due 2025

* EXACT SCIENCES ANNOUNCES OFFERING OF $500 MILLION CONVERTIBLE SENIOR NOTES DUE 2025 Source text for Eikon: Further company coverage:

12 Jan 2018

BRIEF-Exact Sciences Says "Comfortable" With Current 2018 Consensus Revenue Estimate Of Around $417 Mln

* EXACT SCIENCES CORP SAYS "COMFORTABLE" WITH CURRENT 2018 CONSENSUS REVENUE ESTIMATE OF AROUND $417 MILLION Source text for Eikon: Further company coverage:

10 Jan 2018

BRIEF-Exact Sciences Says On Dec. 15, Co, Unit Entered Loan, Security Agreement For 24-Month Secured Revolving Credit Facility For Up To $15.0 Mln

* EXACT SCIENCES - ON DEC. 15, CO, UNIT ENTERED LOAN, SECURITY AGREEMENT FOR 24-MONTH SECURED REVOLVING CREDIT FACILITY FOR UP TO $15.0 MILLION - SEC FILING

18 Dec 2017

BRIEF-Exact Sciences reports qtrly loss per share of $0.23

* Exact Sciences Corp qtrly loss per share $0.23; qtrly revenue $72.6 million, up 158 percent

31 Oct 2017

Exact Sciences revenue beats on strong Cologuard volumes

Oct 30 Exact Sciences Corp reported quarterly revenue that blew past analysts' estimates as demand for the company's sole diagnostic test, Cologuard, more than doubled.

31 Oct 2017

Competitors

  Price Chg
Quest Diagnostics Inc (DGX.N) $101.15 +1.41
Epigenomics AG (ECXn.F) €3.74 --
GeneNews Ltd (GEN.TO) $0.09 0.00

Earnings vs. Estimates